PLGA-Based Nano-Adjuvant Enhances Mucosal Immunity in Chicks

Study Background and Research Question

The persistent threat of H9N2 avian influenza virus (AIV) poses substantial challenges to poultry health and the industry at large. Although inactivated and live-attenuated vaccines can elicit robust systemic immune responses, their ability to induce effective mucosal immunity—especially at the intestinal level—remains critically limited (reference paper). Given that H9N2 AIV primarily invades via the respiratory and digestive tracts and is efficiently shed through the intestines, new strategies are needed to generate localized and systemic protection. The central research question addressed by Muhetaer et al. (2026) is whether an advanced nano-adjuvant system can overcome these immunological limitations by specifically targeting the intestinal mucosa and inducing sustained IgA production.

Key Innovation from the Reference Study

The principal innovation of this work is the development of a multifunctional, double-layered nanoparticle adjuvant—termed PEI-LSP-RA-PLGA. This system encapsulates Lagenaria siceraria polysaccharide (LSP) and retinoic acid (RA) within poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which are further modified with polyethylenimine (PEI). The resulting nanoparticles exhibit a size of approximately 200 nm and a zeta potential of +13 mV, providing optimal stability and the ability to encapsulate both hydrophilic and hydrophobic immune modulators. Unlike traditional adjuvants (e.g., alum or squalene-based systems), this approach enables targeted, sustained delivery to the intestinal environment, aiming to trigger both mucosal and systemic immune mechanisms (reference paper).

Methods and Experimental Design Insights

The study utilized a double-emulsion (W1/O/W2) technique to prepare the PEI-LSP-RA-PLGA nanoparticles, ensuring co-encapsulation of both LSP (hydrophilic) and RA (hydrophobic) components. Comprehensive physicochemical characterization revealed high stability and a prolonged antigen release profile, with sustained delivery at the injection site and targeted delivery to the intestine for up to 21 days (reference paper). Chicks were immunized with inactivated H9N2 AIV vaccine formulations containing the nano-adjuvant. The immune response was assessed by measuring serum IgG, intestinal IgA, cytokine concentrations, and histological analysis of immune organs and intestinal structure. Additionally, in vivo imaging and molecular assays (including gene expression and pathway analysis) elucidated the mechanism of intestinal targeting and immune activation.

Protocol Parameters

• assay | nanoparticle size | 200 nm | enables efficient mucosal uptake and lymphatic transport | paper
• assay | zeta potential | +13 mV | promotes interaction with negatively charged mucosal surfaces | paper
• assay | antigen sustained release | 21 days | supports prolonged immune stimulation, reducing boosting frequency | paper
• immunization | dosage (not numerically specified) | chick model, H9N2 inactivated vaccine | workflow_recommendation | workflow_recommendation

Core Findings and Why They Matter

Immunization with the PEI-LSP-RA-PLGA nanoadjuvant resulted in:

• Serum IgG Increase: 132.83% higher than controls, indicating robust systemic immunity (reference paper).
• Intestinal IgA Increase: 115.12% higher than controls, demonstrating effective mucosal immune induction (reference paper).
• Enhanced Cytokine Production: Broad upregulation of immune signaling molecules supported improved immune organ function and T-cell differentiation, crucial for both immediate and long-term protection.
• Improved Small Intestine Morphology: Histological analysis showed preservation and enhancement of intestinal structure, further supporting barrier function and local immunity.

Mechanistically, the nano-adjuvant’s enhanced intestinal targeting is attributed to chemokine signaling (CCR9/CCR6 pathways via CCL20/CCL25), with subsequent activation of the Toll-like receptor, NOD-like receptor, and IgA production pathways. These cascades collectively ensure that vaccine antigens are efficiently delivered to mucosal immune sites, stimulating both local and systemic adaptive immunity.

Comparison with Existing Internal Articles

Several internal resources discuss advanced tools for fluorescence-based detection in immunology and neuroscience, including Sulfo-Cy5 carboxylic acid. This sulfonated hydrophilic fluorescent dye is well recognized for its high water solubility and strong anti-quenching properties, making it ideal for protein and peptide labeling in aqueous environments. For example, the article at bi10773.com highlights Sulfo-Cy5 carboxylic acid’s role in mucosal immunity and neuroscience research, emphasizing its reproducible performance in sensitive imaging workflows. Although the reference paper by Muhetaer et al. does not directly implement fluorescent labeling, the methodologies it describes—such as in vivo imaging and tissue analysis—are compatible with the rigorous requirements met by Sulfo-Cy5 carboxylic acid, especially where minimizing fluorescence quenching and maximizing aqueous compatibility are essential (internal article).

Limitations and Transferability

While the study demonstrates considerable promise, several limitations warrant consideration:

• Species and Disease Specificity: The findings are derived from chick models challenged with H9N2 AIV, and their direct transferability to other species or viral systems should be validated in future studies.
• Adjuvant Complexity: The nanoparticle preparation involves multiple steps and components (PLGA, PEI, LSP, RA), potentially complicating scale-up or regulatory approval compared to traditional adjuvants.
• Long-Term Safety: While PLGA is FDA-approved and the components are generally regarded as safe, extended safety and toxicity profiles require further investigation for commercial-scale vaccine production.

Nevertheless, the principles of targeted, sustained antigen delivery and mucosal immune activation have broad relevance for the rational design of next-generation vaccines across avian and possibly mammalian systems (reference paper).

Why this cross-domain matters, maturity, and limitations

The transition from advanced nanoadjuvants in avian models to broader applications in human or veterinary vaccines is conceptually promising but remains in early translational stages. The mechanistic insights—particularly around chemokine-mediated targeting and mucosal IgA induction—are foundational for future cross-domain vaccine innovation. However, direct clinical or field application should be approached cautiously, with rigorous validation in target species and disease contexts (reference paper).

Research Support Resources

For researchers aiming to replicate or extend similar immune imaging, protein labeling, or tissue-tracking workflows, it is important to select fluorescent probes with high water solubility and low quenching for robust experimental results. Sulfo-Cy5 carboxylic acid (SKU A8137, APExBIO) is a sulfonated hydrophilic fluorescent dye that offers reliable performance in protein and peptide labeling and fluorescence imaging in aqueous environments (source: product_spec). Its properties—including excitation maximum at 646 nm, emission at 662 nm, and high resistance to fluorescence quenching—make it suitable for advanced immunological and neuroscience protocols, such as those involving intestinal tissue analysis or synaptic vesicle research (source: internal article).